zacks.com · 22 jun

Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

businesswire.com · 15 jun

Alcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada

MONTRÉAL--(BUSINESS WIRE)--Alcon announces the launch and Canadian availability of UNITY® Cataract System (CS), Alcon's next-generation standalone cataract surgical platform.

newsfilecorp.com · 15 jun

Mexican Gold Announces Subscription Receipt Financing and Loan to Alcon Silver in Connection with Arrangement

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2026) - Mexican Gold Mining Corp. (TSXV: MEX) ("Mexican Gold" or the "Company") and Alcon Silver Corp. ("Alcon") announce that, in connection with the previously announced arrangement agreement dated April 8, 2026 between the Company and Alcon (the "Arrangement Agreement"), the Company intends to complete a non-brokered private placement of up to 11,250,000 subscription receipts of the Company (the "Subscription Receipts") at a price of $0.20 per Subscription Receipt, for aggregate gross proceeds of up to $2,250,000 (the "Offering"). The Offering constitutes a concurrent financing to the Arrangement (as defined below) and is subject to acceptance of the TSX Venture Exchange (the "TSXV").

gurufocus.com · 4 jun

Is It Too Late to Buy Alcon Inc (ALC) After 3.7% Rally? GF Value Says Undervalued

On June 04, 2026, Alcon Inc (ALC) shares rose 3.7% today, closing at $66.58. The stock has seen considerable volatility over the past year, with a 52-week high

seekingalpha.com · 31 may

Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)

Alcon receives a buy rating, driven by the launch of Tryptyr in the mature dry eye disease market. Tryptyr's unique mechanism and rapid tear production differentiate it, but commercial adoption hinges on refill rates, payer coverage, and patient persistence. ALC's robust commercial footprint and strong balance sheet support ongoing R&D, M&A, dividends, and buybacks, mitigating financing risks.

zacks.com · 28 may

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.

zacks.com · 7 may

Here's Why Alcon (ALC) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

businesswire.com · 7 may

Algoma Central Corporation Reports Financial Results for the 2026 First Quarter

ST. CATHARINES, Ontario--(BUSINESS WIRE)--Algoma Central Corporation (TSX: ALC) ("Algoma", the "Company") today reported its results for the three months ended March 31, 2026. Algoma reported first quarter revenues of $127,781, compared to revenues of $107,201 in 2025. Net earnings for the first quarter were $2,224 compared to a loss of $23,280 in 2025. Earnings in 2026 include one-time net gains totaling $18,881 in the period. Due to the closing of the canal system and the winter weather condi.